LONDON – AstraZeneca said Monday that late stage trials of its COVID-19 vaccine developed with Oxford University were “highly effective’’ in preventing disease.The results are based on interim analysis of trials in the U.K.
and Brazil of the vaccine developed by Oxford University and manufactured by AstraZeneca. No hospitalizations or severe cases of COVID-19 were reported in those receiving the vaccine, AstraZeneca said.“These findings show that we have an effective vaccine that will save many lives.
Excitingly that one of our dosing regimens may be around 90% effective,’’ said Professor Andrew Pollard, the chief investigator for the trial.The trial looked at two different dosing regimens — a half dose of the vaccine followed by a full.